Table 2. Tumour and normal cell line expression of CD133 and sensitivity to anti-CD133 antibody-drug conjugate, AC133-vcMMAF.
| Cell line | CD133 copies per cella | Cytotoxicity IC50 (ng ml−1)b | Growth inhibition IC50 (ng ml−1)b |
|---|---|---|---|
| Hepatocellular | |||
| Hep3B | 66 000 | 5.2±1.0 | 2.2±0.8 |
| HepG2 | 10 000 | >10 000 | >10 000 |
| Gastric | |||
| KATO III | 12 000 | 9.5 | 7.0 |
| AGS | 6500 | 10 000 | 10 000 |
| Pancreatic | |||
| Su.86.86 | 36 000 | >10 000 | >10 000 |
| Capan-1 | 30 000 | >10 000 | >10 000 |
| Normal cells | |||
| Renal epithelial | 800 | >10 000 | >10 000 |
| Hepatocytes | Not detected | >10 000 | Not tested |
a
CD133 expression was estimated by quantitative FACS.
b
IC50 values (mean±s.e.m.) were calculated as described in Materials and methods from ⩾3 or more independent experiments, except for KATO III (n=2).